The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis

Justine Hum, Joseph J. Shatzel, Janice Jou, Thomas Deloughery

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Introduction: The coagulopathy of cirrhosis is complex, placing patients at risk for both bleeding and thrombosis. Direct oral anticoagulants (DOACs) have equivalent or superior efficacy and safety as compared to vitamin K antagonists (VKAs); however, their efficacy and safety in liver cirrhosis has not been studied. To better define this, we evaluated outcomes of patients with cirrhosis prescribed DOACs compared to other anticoagulants at our center. Methods: Retrospective cohort study of patients with cirrhosis prescribed therapeutic anticoagulation over a 3-year period for thrombosis or prevention of stroke in patients with atrial fibrillation. The primary outcomes of interest were bleeding events and recurrent thrombosis or stroke. Results: During the study period, 27 patients with cirrhosis were prescribed a DOAC and 18 were prescribed VKA or low molecular weight heparin (LMWH). Both groups had similar total bleeding events (8 DOAC vs 10 other, P=.12). There were significantly less major bleeding episodes in the DOAC group (1 [4%] vs 5 [28%], P=.03). Recurrent thrombosis occurred in one patient receiving a DOAC (4%) and one patient (6%) receiving other anticoagulation (P=1.0). Conclusions: Direct oral anticoagulant use in patients with cirrhosis may be as safe as traditional anticoagulants. Patients with cirrhosis at our center prescribed DOACs had less major bleeding events, while maintaining efficacy at preventing stroke or thrombosis.

Original languageEnglish (US)
JournalEuropean Journal of Haematology
DOIs
StateAccepted/In press - 2017

Fingerprint

Anticoagulants
Fibrosis
Safety
Thrombosis
Hemorrhage
Vitamin K
Stroke
Low Molecular Weight Heparin
Liver Cirrhosis
Atrial Fibrillation
Cohort Studies
Retrospective Studies

Keywords

  • Anticoagulation
  • Bleeding
  • Cirrhosis
  • Rivaroxaban
  • Warfarin

ASJC Scopus subject areas

  • Hematology

Cite this

@article{6ed0aa6f98e84682bdb505f37c3a2c10,
title = "The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis",
abstract = "Introduction: The coagulopathy of cirrhosis is complex, placing patients at risk for both bleeding and thrombosis. Direct oral anticoagulants (DOACs) have equivalent or superior efficacy and safety as compared to vitamin K antagonists (VKAs); however, their efficacy and safety in liver cirrhosis has not been studied. To better define this, we evaluated outcomes of patients with cirrhosis prescribed DOACs compared to other anticoagulants at our center. Methods: Retrospective cohort study of patients with cirrhosis prescribed therapeutic anticoagulation over a 3-year period for thrombosis or prevention of stroke in patients with atrial fibrillation. The primary outcomes of interest were bleeding events and recurrent thrombosis or stroke. Results: During the study period, 27 patients with cirrhosis were prescribed a DOAC and 18 were prescribed VKA or low molecular weight heparin (LMWH). Both groups had similar total bleeding events (8 DOAC vs 10 other, P=.12). There were significantly less major bleeding episodes in the DOAC group (1 [4{\%}] vs 5 [28{\%}], P=.03). Recurrent thrombosis occurred in one patient receiving a DOAC (4{\%}) and one patient (6{\%}) receiving other anticoagulation (P=1.0). Conclusions: Direct oral anticoagulant use in patients with cirrhosis may be as safe as traditional anticoagulants. Patients with cirrhosis at our center prescribed DOACs had less major bleeding events, while maintaining efficacy at preventing stroke or thrombosis.",
keywords = "Anticoagulation, Bleeding, Cirrhosis, Rivaroxaban, Warfarin",
author = "Justine Hum and Shatzel, {Joseph J.} and Janice Jou and Thomas Deloughery",
year = "2017",
doi = "10.1111/ejh.12844",
language = "English (US)",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis

AU - Hum, Justine

AU - Shatzel, Joseph J.

AU - Jou, Janice

AU - Deloughery, Thomas

PY - 2017

Y1 - 2017

N2 - Introduction: The coagulopathy of cirrhosis is complex, placing patients at risk for both bleeding and thrombosis. Direct oral anticoagulants (DOACs) have equivalent or superior efficacy and safety as compared to vitamin K antagonists (VKAs); however, their efficacy and safety in liver cirrhosis has not been studied. To better define this, we evaluated outcomes of patients with cirrhosis prescribed DOACs compared to other anticoagulants at our center. Methods: Retrospective cohort study of patients with cirrhosis prescribed therapeutic anticoagulation over a 3-year period for thrombosis or prevention of stroke in patients with atrial fibrillation. The primary outcomes of interest were bleeding events and recurrent thrombosis or stroke. Results: During the study period, 27 patients with cirrhosis were prescribed a DOAC and 18 were prescribed VKA or low molecular weight heparin (LMWH). Both groups had similar total bleeding events (8 DOAC vs 10 other, P=.12). There were significantly less major bleeding episodes in the DOAC group (1 [4%] vs 5 [28%], P=.03). Recurrent thrombosis occurred in one patient receiving a DOAC (4%) and one patient (6%) receiving other anticoagulation (P=1.0). Conclusions: Direct oral anticoagulant use in patients with cirrhosis may be as safe as traditional anticoagulants. Patients with cirrhosis at our center prescribed DOACs had less major bleeding events, while maintaining efficacy at preventing stroke or thrombosis.

AB - Introduction: The coagulopathy of cirrhosis is complex, placing patients at risk for both bleeding and thrombosis. Direct oral anticoagulants (DOACs) have equivalent or superior efficacy and safety as compared to vitamin K antagonists (VKAs); however, their efficacy and safety in liver cirrhosis has not been studied. To better define this, we evaluated outcomes of patients with cirrhosis prescribed DOACs compared to other anticoagulants at our center. Methods: Retrospective cohort study of patients with cirrhosis prescribed therapeutic anticoagulation over a 3-year period for thrombosis or prevention of stroke in patients with atrial fibrillation. The primary outcomes of interest were bleeding events and recurrent thrombosis or stroke. Results: During the study period, 27 patients with cirrhosis were prescribed a DOAC and 18 were prescribed VKA or low molecular weight heparin (LMWH). Both groups had similar total bleeding events (8 DOAC vs 10 other, P=.12). There were significantly less major bleeding episodes in the DOAC group (1 [4%] vs 5 [28%], P=.03). Recurrent thrombosis occurred in one patient receiving a DOAC (4%) and one patient (6%) receiving other anticoagulation (P=1.0). Conclusions: Direct oral anticoagulant use in patients with cirrhosis may be as safe as traditional anticoagulants. Patients with cirrhosis at our center prescribed DOACs had less major bleeding events, while maintaining efficacy at preventing stroke or thrombosis.

KW - Anticoagulation

KW - Bleeding

KW - Cirrhosis

KW - Rivaroxaban

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85010298688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010298688&partnerID=8YFLogxK

U2 - 10.1111/ejh.12844

DO - 10.1111/ejh.12844

M3 - Article

C2 - 28009449

AN - SCOPUS:85010298688

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

ER -